[팜뉴스=김태일 기자] A personalized metastatic colorectal cancer treatment plan has been prepared. Professor Kim Eun-seon from the Department of Gastroenterology at Korea University Anam Hospital said that Cetuximab, a targeted treatment commonly used to treat metastatic colorectal cancer, binds to EGFR epidermal growth), which is involved in the development of cancer, and then decomposes and has been noted to inhibit the proliferation of cancer cells. The developed Cetux probe was designed to emit fluorescence when cetuximab is decomposed, and it was revealed that the higher the fluorescence intensity, the greater the therapeutic effect of cetuximab. This is significant as it serves as a starting point to effectively reduce the time and cost required for future treatment of metastatic colorectal cancer. We met Professor Kim Eun-seon from the Department of Gastroenterology at Korea University Anam Hospital and heard the Cetux probe in detail.
# What motivated you to start research?
I have always been interested in and continued to research markers that can observe changes in living tissue in colon cancer, tissue of which can be obtained through an endoscope. In 2019, I went to KIST for training, which was an opportunity to start joint research with Dr. Joohee Ryu from KIST. Dr. Joohee Ryu is a scholar who is conducting research with eminent scientists in Boston, and it was a great opportunity for me to do research together.
# The reason why we focus on Cetuximab.
To administer cetuximab, the administration decision is made based on the location of the patient’s colon tumor and the results of immunohistochemical and genetic testing of the colon tumor tissue. However, the response to treatment can be assessed after carrying out a CT scan after 6 weeks. Cetuximab is a drug that not only has therapeutic effects but also side effects, so if the response to treatment is known in advance, a more personalized and precise medical treatment can be performed.
#The effectiveness has been confirmed through animal tests. What were the results?
In animal experiments, it was confirmed using the Cetux probe that cetuximab binds to EGFR, enters cells and decomposes, resulting in a therapeutic response effect. The Cetux probe is designed to fluoresce when cetuximab is broken down, showing a correlation that the higher the fluorescence intensity, the greater the therapeutic effect of cetuximab.
# There are high expectations that it will provide optimized treatment for each individual. The reason is.
Cetuximab is one of the leading targeted treatments for metastatic colorectal cancer. If the response to treatment can be predicted in advance, targeted therapeutic drugs determined by information about specific genetic mutations and the location of the colon cancer can be selected as a more precisely optimized treatment for each individual.
#The research results were published in “Biomaterials”. The reason why biomaterials have attracted attention.
This is believed to be because the fluorescence intensity directly represents the process in which the Cetux probe binds to the EGFR, moves into the cell and decomposes. It has been noted that this is similar to the treatment principle on which setoximab actually works, so it is likely to have a high correlation with treatment response.
# Future projects.
We are further solidifying our trusted joint research relationship with Dr. Joohee Ryu of KIST and are planning further research to gain clinical application data and commercialize it.
2024-01-18 21:00:00
#Focus #Cetuximab #Degradation #Reducing #Treatment #Times #Reducing #Costs #Metastatic #Colorectal #Cancer